Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Koninklijke Philips N.V. is the Netherlands-based health technology company. The Company's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other and Legacy Items. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care & Health Informatics businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The HealthTech Other segment comprises such items, as innovation, emerging businesses, royalties, among others. The Legacy Items segment consists mainly of separation costs, legacy legal items, legacy pension costs, among others.

  • Revenue in EUR (TTM)19.54bn
  • Net income in EUR1.20bn
  • Incorporated2000
  • Employees81.59k
  • Location
    Royal PhilipsBreitner Center, Amstelplein 2AMSTERDAM 1096 BCNetherlandsNLD
  • Phone+31 205977777
  • Fax+31 205977220
  • Websitehttps://www.philips.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PHIA:AEX since
announced
Transaction
value
Capsule Technologies IncAnnounced19 Jan 202119 Jan 2021Announced12.91%635.00m
Intact Vascular IncAnnounced27 Aug 202027 Aug 2020Announced19.00%360.00m
Acerde SASDeal completed23 Jul 202023 Jul 2020Deal completed12.51%--
Innovative Imaging Technologies IncDeal completed29 Jun 202029 Jun 2020Deal completed23.54%--
Data delayed at least 15 minutes, as of Apr 16 2021 16:35 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Demant A/S1.95bn150.71m9.86bn16.16k65.158.8634.195.074.684.6860.3434.390.66182.164.59895,636.005.198.548.2613.7971.4675.257.8411.170.648.880.5210.00-3.196.29-23.32-4.835.23--
Ambu A/S513.57m38.99m10.18bn4.20k291.8335.12158.7619.821.161.1615.299.660.78582.637.61912,347.805.978.387.1510.7063.2758.457.5910.771.055.110.439130.0826.4913.56-23.979.6632.838.83
GN Store Nord A/S1.81bn168.32m10.43bn6.53k56.7013.5833.725.779.629.62103.4340.150.80624.064.902,061,149.007.619.0810.8511.9854.2659.909.4411.290.9535108.730.530718.186.9611.64-13.8910.889.727.93
Carl Zeiss Meditec AG1.33bn129.89m13.10bn3.29k100.48----9.821.461.4614.93--------405,669.30--7.94--9.9655.9355.469.8210.17--7.06--36.70-8.495.13-23.3914.4621.815.64
Smith & Nephew plc3.81bn373.84m14.61bn17.91k39.123.3017.343.840.36820.36823.754.360.4490.84483.59184,057.104.417.915.259.5769.3972.899.8213.701.7611.020.411446.96-11.25-0.3214-25.331.794.35-5.59
Sonova Holding AG2.32bn382.75m15.48bn14.35k39.647.3627.446.676.695.2640.5736.020.51382.826.30168,611.708.5210.5710.7013.2770.8769.9216.5815.592.2633.460.446732.875.567.47-7.713.097.68--
Straumann Holding AG1.29bn82.77m18.01bn7.02k220.2116.47103.5813.935.675.6789.5475.810.57741.764.24203,257.503.7413.464.6516.2572.2275.296.4718.552.477.610.365234.41-10.6712.29-70.225.2518.467.53
Coloplast A/S2.50bn570.17m26.46bn12.50k50.0036.6538.7010.6019.8819.8887.0427.121.322.886.301,494,327.0030.1331.5761.8354.5767.8867.8822.8422.680.566617.460.44789.513.375.928.3736.098.587.57
Sartorius Stedim Biotech SA1.91bn357.05m35.38bn7.57k99.1924.2376.2818.523.873.8720.6915.840.77732.267.99252,469.1014.7113.9318.7018.3052.5051.7118.9316.820.7097--0.283520.4232.5916.6552.6024.8424.6115.33
Koninklijke Philips NV19.54bn1.20bn46.04bn81.59k39.473.8516.892.361.281.2721.1213.110.71393.734.49239,423.004.413.986.045.6944.9546.276.176.031.0640.560.3681--0.2723.060.927552.532.611.63
Siemens Healthineers AG14.74bn1.54bn52.76bn54.50k31.194.1222.253.581.501.5014.4111.350.61383.874.38272,981.506.476.649.0810.9839.2040.2210.5510.081.0663.050.0379---0.39952.25-9.962.029.37--
EssilorLuxottica SA14.43bn85.00m61.06bn144.51k790.501.8826.654.230.17590.175932.8773.840.27512.976.4599,846.380.28412.820.32383.3657.8160.531.037.471.9110.640.266259.39-17.0316.53-92.11-35.4214.7314.97
Data as of Apr 16 2021. Currency figures normalised to Royal Philips's reporting currency: Euro EUR

Institutional shareholders

15.80%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 28 Feb 202122.42m2.46%
Norges Bank Investment Managementas of 31 Dec 202020.59m2.26%
Wellington Management Co. LLPas of 31 Dec 202016.88m1.85%
Amundi Asset Management SA (Investment Management)as of 22 Jun 202014.28m1.57%
BlackRock Fund Advisorsas of 08 Apr 202113.13m1.44%
DWS Investment GmbHas of 08 Apr 202112.76m1.40%
Fidelity Management & Research Co. LLCas of 28 Feb 202112.51m1.37%
Capital Research & Management Co. (World Investors)as of 31 Dec 202010.67m1.17%
BlackRock Investment Management LLCas of 11 Apr 202110.55m1.16%
FIL Investment Advisors (UK) Ltd.as of 28 Feb 202110.11m1.11%
More ▼
Data from 31 Dec 2020 - 31 Dec 2020Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.